Welcome to our dedicated page for Crescent Biopharma news (Ticker: CBIO), a resource for investors and traders seeking the latest updates and insights on Crescent Biopharma stock.
Crescent Biopharma reports news about its clinical-stage oncology pipeline, including CR-001, a PD-1 x VEGF bispecific antibody, and antibody-drug conjugate programs such as CR-002 and CR-003. Company updates commonly cover clinical trial activity in solid tumors, pipeline combinations, collaboration activity, financial results, and business highlights.
Recurring corporate announcements also include investor conference presentations and equity inducement awards under the company’s employment inducement incentive plan. These updates reflect Crescent’s status as a Nasdaq-listed biotechnology issuer focused on cancer therapeutics.
Catalyst Biosciences (CBIO) reported its Q3 2021 financial results and announced the discontinuation of MarzAA development to focus on complement therapeutics. The decision stems from enrollment challenges and competition in clinical trials. The company plans to seek buyers for its hemophilia assets and anticipates a 40% reduction in burn rate. Financially, Q3 net loss was $25.2 million, compared to $16 million a year prior, with cash reserves of $64.5 million. Catalyst aims to advance its complement program, with notable progress in CB 4332 and ongoing trials.
Catalyst Biosciences, Inc. (NASDAQ: CBIO) announced that Dr. Grant Blouse will present at two scientific conferences from October 26-30, 2021. The presentations will focus on the ProTUNE™ platform, engineered for potency and specificity in complement-mediated disorders. Dr. Blouse expressed excitement about ProTUNE™ and its C3b/C4b degraders' potential in precision medicine. Catalyst's pipeline includes CB 4332, an enhanced complement factor I protease expected to enter clinical trials in 2022, alongside late-stage programs for treating rare bleeding disorders.
Catalyst Biosciences, Inc. (NASDAQ: CBIO) announced the resignation of its CFO, Clinton Musil, effective October 29, 2021, for personal reasons. Seline Miller, the controller, is elevated to interim CFO and principal accounting officer while a successor is sought. The CEO, Nassim Usman, expressed gratitude for Musil's contributions as the company advances in its Protease Medicines platform. Catalyst is focused on rare disorders with late-stage programs like MarzAA and preclinical candidates targeting rare diseases.
Catalyst Biosciences, Inc. (NASDAQ: CBIO) announced that the U.S. FDA has granted Orphan Drug Designation for its candidate, Marzeptacog alfa (MarzAA), aimed at treating Factor VII Deficiency (FVIID). This is the second ODD for MarzAA, which also holds Fast Track Designation for treating Hemophilia A/B with inhibitors and FVIID. The Orphan Drug Designation supports drug development for rare diseases, providing tax credits and marketing exclusivity. Catalyst focuses on rare disorders of the coagulation and complement systems, with MarzAA being a key part of its late-stage clinical programs.
Catalyst Biosciences (NASDAQ: CBIO) will participate in a fireside chat at the Cantor Global Healthcare Conference on September 29, 2021, at 10:00 am ET. Members of the executive management team will discuss the company's advancements, including its late-stage clinical programs targeting rare disorders. Investors can access the live webcast here, with an archived version available for 90 days.
Catalyst Biosciences reported that its management team will participate in a fireside chat on September 15, 2021, focusing on advancements in its complement portfolio, particularly CB 2782-PEG for dry age-related macular degeneration (AMD). The discussion will cover key programs including CB 4332 and various C3 and C4 degraders. The company highlighted its commitment to addressing unmet needs in rare disorders and the potential advantages of its preclinical and clinical candidates. A replay of the call will be available on its website.
Catalyst Biosciences (NASDAQ: CBIO) recently presented at the International Conference on Complement Therapeutics (ICCT) from September 8-13, 2021. The focus was on the engineered Complement Factor I (CFI), particularly CB 4332, demonstrating improved pharmacokinetics and efficacy compared to plasma-derived CFI in preclinical models. This first-in-class product aims for weekly subcutaneous administration in patients with CFI deficiency. Catalyst has initiated the ConFIrm study to confirm CFI deficiencies, supporting future IND submissions and global clinical trials for CB 4332.
Catalyst Biosciences (NASDAQ: CBIO) announced the appointment of Jeanne Jew to its Board of Directors, bringing over 25 years of corporate development experience. CEO Nassim Usman expressed excitement regarding her expertise to support the advancement of the company’s Protease Medicines pipeline. Jew has held significant roles in various biopharmaceutical companies, enhancing strategic planning and business development. Catalyst focuses on addressing unmet medical needs in rare disorders with its protease engineering platform, which includes late-stage clinical programs like MarzAA.
Catalyst Biosciences, Inc. (CBIO) announced its second-quarter financial results for 2021, reporting a net loss of $19.9 million, or $0.64 per share, compared to $17.2 million, or $0.96 per share, in 2020. The company had cash reserves of $86.5 million. R&D expenses increased by 19% to $15.4 million, driven by higher clinical and personnel costs. Catalyst continues to advance its complement and hemostasis programs, notably with the launch of the ConFIrm study for CB 4332 and ongoing trials for MarzAA. The company outlined its expected milestones for future development.
Catalyst Biosciences (NASDAQ: CBIO) announced the launch of the ConFIrm study, screening patients for Complement Factor I (CFI) deficiencies to develop CB 4332, an enhanced CFI treatment. The first patient has been screened, aiming for a Phase 1/2 trial in mid-2022. This study will evaluate CFI levels and disease manifestations linked to CFI deficiency, which can lead to severe immune disorders. Catalyst's complement portfolio also includes CB 2782-PEG for dry age-related macular degeneration, licensed to Biogen, with a focus on addressing rare complement-related disorders.